Send me real-time posts from this site at my email
Zacks

Zoetis (ZTS) Librela Gets Marketing Authorization in Europe

Zoetis Inc. ZTS announced that the European Commission granted marketing authorization to Librela (bedinvetmab), an injectable monoclonal antibody (mAb) therapy for monthly alleviation of osteoarthritis (OA) pain in dogs. Librela is the first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs.

Shares of the company have increased 25.3% year to date against the industry’s decline of 4.3%.

Bedinvetmab has a unique mode of action, inhibiting Nerve Growth Factor—a key player in osteoarthritis pain— which effectively controls OA pain for a month along with offering a positive safety profile.

Bedinvetmab administered as monthly injections during the pivotal, field three-month study demonstrated a reduction in osteoarthritis pain as compared to placebo-controlled dogs. Furthermore, this pain reduction was maintained throughout the six-month continuation study,demonstrating sustained efficacy of bedinvetmab for at least nine months.

OA can affect many areas of a pet’s life, including sleep, cognitive function, affect (emotion) and social relationships, among several other factors.

Unlike other pain indications, Librela combines one month of pain control and increased mobility, with a proven safety and efficacy profile.

Zacks Rank and Stocks to Consider

Zoetis currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Cassava Sciences Inc. SAVA, BioLineRx Ltd, BLRX and Catalent Inc. CTLT. All stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Cassava’s loss per share estimates have narrowed from 26 cents to 21 cents for 2020 in the past 60 days. Shares of the company have increased 116.1% year to date.

BioLineRx’s loss per share estimates have narrowed from $1.95 to $1.67 for 2020 and from $1.44 to $1.36 for 2021 in the past 60 days. Shares of the company have increased 4.4% year to date.

Catalent’s earnings per share estimates have increased from $2.41 to $2.51 for 2020 and from $2.82 to $2.93 for 2021 in the past 60 days. Shares of the company have decreased 81.8% year to date.

 

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Zoetis Inc. (ZTS): Free Stock Analysis Report
 
BioLineRx Ltd. (BLRX): Free Stock Analysis Report
 
Catalent, Inc. (CTLT): Free Stock Analysis Report
 
Cassava Sciences, Inc. (SAVA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue